Category Archives: Biotechnology

Your May 17 article about genetic engineering [Facts, Fears and the Future of Food] is so chock-full of glib falsehoods that I hardly know where to begin. I would have far more respect for the science behind biotechnology if it didnt depend so heavily on half-truths, double standards, unwarranted assumptions, blurred distinctions and conflicts of interest. Jack Britt says that the same microorganisms move genes between species both in nature and in genetic engineering, and therefore the methods are the same. This is half true. In the latter, various techniques are employed to either bypass or weaken the natural immunity of the organism being manipulated, often literally forcing the DNA into the cells in ways that would never occur in nature. Stating that many organisms are naturally GMO, and therefore implying that we have carte blanche to do whatever we wish, isnt just a stretch, its a whopper. Britt and Leah McGrath emphasize the precision of these techniques. Again, this is a perversion of the truth. In fact, this is merely a precision of abstractions, because the living organism is then going to move these genes around in ways that cant possibly be controlled or predicted. The only way to … Continue reading →

Signalling Keralas intention to transform itself into one of the top destinations in the biotechnology sector, scientists, technologists and technocrats have pledged support to the government in its efforts to promote the establishment of biotech industries. A conclave organised by the Kerala Biotechnology Commission (KBC) here on Thursday stressed the need to harness the immense biological resources and human potential in the State to create an enabling ecosystem and attract investments in the sector. Inaugurating the event, Minister for Water Resources Mathew T.Thomas said Kerala, with its rich biodiversity, unique spices and traditional systems of medicine offered unprecedented opportunities for biotechnology- based industries. Pointing out that the sector had registered low growth, despite the governments efforts to improve infrastructural facilities, the Minister said the Biotechnology Park at Kalamassery and the Life Sciences Park at Thiruvananthapuram would be promoted as hubs of biotechnology- based industries. Biotechnology, the Minister said, could play a major role in increasing agricultural productivity as well as in other sectors like the environment, animal husbandry, bio fuels and aquaculture. Ecosystem The government was committed to the creation of an ecosystem for the establishment of biotech- based industries, the Minister added. Presiding over the inaugural function, V.K.Ramachandran, Vice … Continue reading →

As Boulders biotech community continues to thrive and grow, theJennie Smoly Caruthers Biotechnology Buildingdebuted its state-of-the-art E-Wing on Monday. The 56,340-square-foot E-Wingwill feature next-generation active learning spaces where students learn by doing rather than by being lectured, as well as laboratory space wherecurrent and future faculty in the BioFrontiers Instituteand the Department of Chemicaland Biological Engineering will be able tocontinue their groundbreaking research. Mondays ribbon-cutting event honored Colorado-based philanthropists John and Anna Sie, whose generous $2 million gift will allow for the creation of an industry co-location space on the E-Wings second floor. The space will be leased to industry partners, allowing local and national biotech companies to bring scientists and resources on-site in order to work side-by-side with university students and researchers. CU Boulder Chancellor Philip DiStefano and Tom Cech, Nobel Laureate and director of the BioFrontiers Institute, were on hand to officially open the Yuan Yung-Foo Interdisciplinary Bioscience Research Neighborhood and thanked the Sies for their continued support of BioFrontiers and the universitys research mission. The Sies, whose philanthropic generosity is well known in the state of Colorado and around the world, have provided stalwart support for the BioFrontiers Institute for many years and in many ways, said … Continue reading →

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of two abstracts on its drug neratinib that will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, which will be held September 8 12 in Madrid, Spain. Abstracts are available to the public online on the ESMO website: http://www.esmo.org. Abstract #1490: Neratinib after trastuzumab-based adjuvant therapy in early stage HER2-positive breast cancer:5-year analysis of the Phase III ExteNET trial.The abstract will be presented as a proffered paper oral session on Friday, September 8. Abstract #177P:Effects of neratinib on health-related quality of life in early stage HER2-positive breast cancer.The abstract will be displayed as a poster on Monday, September 11. The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab (Herceptin) in women with early stage HER2-positive breast cancer. U.S. Approval of Neratinib (NERLYNX) Neratinib was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. About HER2-Positive Breast Cancer Approximately 20% to 25% of breast cancer … Continue reading →

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in a panel discussion on breast cancer at 9:00 a.m. EDT on Wednesday, September 6, at Citis 12th Annual Biotech Conference in Boston. A live webcast of the panel discussion will be available on the Companys website at http://www.pumabiotechnology.com. The discussion will be archived on the website and available for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. NERLYNX (neratinib) is approved for commercial use by prescription in the United States as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and is marketed as NERLYNX. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the commercialization of NERLYNX and the continued development of its other advanced drug candidates directed … Continue reading →

Debate about the security implications of cutting-edge biotechnology is afflicted with a fundamental blind spota lack of attention to growing military interest in the field. This blind spot is evident in discussions about, for example, gene-editing technology (in relation both to gene drives and to human modification). Such debate has tended to focus on the idea that research and technology might be directly misused by the bad guysand has tended to ignore broader questions about how the ongoing militarization of cutting-edge fields in biology might contribute to insecurity. Last year James Clapper, when he was US director of national intelligence, labelled emerging population-level genetic-modification techniques as potential weapons of mass destruction. A number of states, in the context of the Biological and Toxin Weapons Convention, have in recent years voiced concerns about state investment into biotechnology. Yet ethical reviews of gene editing to date in the United States have barely touched upon concerns about growing military interest in cutting-edge biotechas reflected in their absence from recent reports on both environmental and human modificationbiotechnology. Such omissions are in keeping with broad trends where US discussions about the potential for misusing biotechnology are concerned. To be sure, the risk that benignly intended … Continue reading →

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, August 7. Philip Morris International (NYSE:PM): "No, don't sell it. I think they have a lot more optionality. I would not sell that here. And remember, I think the dollar's getting very weak still." Blue Apron (NYSE:APRN): Cramer doesn't see upside. International Game Technology (NYSE:IGT): It's an inexpensive stock but does not have a growth catalyst. Eaton Corp (NYSE:ETN): Their quarter was not good. Cramer prefers Honeywell (NYSE:HON) or 3M (NYSE:MMM). DaVita (NYSE:DVA): No. Cramer prefers Boston Scientific (NYSE:BSX) in that group. Puma Biotechnology (NYSE:PBYI): It has had a big run. Book profits. Masimo Corp (NASDAQ:MASI): Cramer just prefers Intuitive Surgical (NASDAQ:ISRG) in that group. :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now! Get Cramer's Picks by email - it's free and takes only a few seconds to sign up Read more from the original source: Book Profits On Puma Biotechnology - Cramer's Lightning Round (8/7/17) - Seeking Alpha … Continue reading →

Market SummaryFollow Puma Biotechnology Inc is a A biopharmaceutical company PBYI - Market Data & News PBYI - Stock Valuation Report Puma Biotechnology Inc (PBYI) had a rough trading day for Thursday August 10 as shares tumbled 9.43%, or a loss of $-7.5 per share, to close at $72.00. After opening the day at $77.00, shares of Puma Biotechnology Inc traded as high as $79.45 and as low as $71.30. Volume was 1.48 million shares over 11,431 trades, against an average daily volume of 1.45 million shares and a total float of 36.97 million. As a result of the decline, Puma Biotechnology Inc now has a market cap of $2.66 billion. In the last year, shares of Puma Biotechnology Inc have traded between a range of $98.85 and $28.35, and its 50-day SMA is currently $86.09 and 200-day SMA is $50.29. For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI. Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today. Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the … Continue reading →

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Biotechnology and Pharmaceuticals are cheaper in Price/Earnings and Price/Free Cash Flow than their historical averages, but they are worse in Price/Sales and profitability measured in ROE (much worse for the pharma industry). Other industries look overvalued by more than 20%. Life Science Tools/Services are significantly above their baseline in profitability, which may partly justify overpricing. Healthcare Equipment is the only group worse than its historical averages in all metrics. Since last month: P/E has improved in Healthcare Technology, Pharmaceuticals and deteriorated in Healthcare Equipment. P/S has improved in Healthcare Equipment, Managed Healthcare and deteriorated in Biotechnology, Pharmaceuticals. P/FCF has improved in Managed Healthcare, Pharmaceuticals and deteriorated in Healthcare Equipment. ROE doesn't show a significant change in any group. In 1 trailing month the SPDR Select Sector Healthcare ETF (XLV), the S&P 500 Pharmaceuticals ETF (XPH) and the Nasdaq Biotechnology ETF (IBB) have underperformed the SPDR S&P 500 ETF (SPY) by about 2%, 6% and 1% respectively. The five best performers among S&P 500 Healthcare stocks on this period are Align Technology Inc (ALGN), … Continue reading →

HYDERABAD: Dr P M Bhargava, eminent scientist and founder-director of the city-based Centre for Cellular and Molecular Biology (CCMB), died here on Tuesday after a brief illness. He was 89 and is survived by two children. Pushpa Mittra Bhargava was born on February 22, 1928. He was a pioneer in the field of biotechnology in India and among the first persons to use the term "genetic engineering". Bhargava was instrumental in the formation of the Department of Biotechnology in the '70s. He was also chairman of Medically Aware and Responsible Citizens of Hyderabad, Sambhavna Trust, Bhopal, and Basic Research, Education and Development Society (BREAD), New Delhi. He served as vice-chairman of the National Knowledge Commission between 2005 and 2007. Bhargava received over 100 national and international honours and awards. He was awarded the Padma Bhushan in 1986 but returned it in 2015 citing "matters of principle". He was honoured with the Legion d'honneur in 1998. He is popularly known as the architect of modern biology in India. Originally posted here: Dr Pushpa Mitra Bhargava, pioneer in biotechnology, passes away at 89 - Times of India … Continue reading →